@article{e042ca7219d740aa895051ce5f164a04,
title = "Targeting the aryl hydrocarbon receptor/polyamine biosynthesis axis of evil for cancer therapy",
abstract = "The polyamine metabolic pathway has been considered a rational target for antineoplastic therapy since it was discovered that polyamines are absolute requirements for tumor initiation, growth, and, in some instances, survival. Although several promising preclinical studies have demonstrated the critical nature of polyamines for tumor growth, the clinical success of agents targeting polyamine metabolism have been lacking. In the accompanying article, Bianchi-Smiraglia et al. identify both a new target and new drug that inhibits polyamine biosynthesis, reduces intracellular polyamines, and inhibits the growth of several models of human multiple myeloma. These results are both intriguing and provide promise for moving such a strategy to the clinic.",
author = "Casero, {Robert A.}",
note = "Funding Information: The author thanks Tracy Murray Stewart (Johns Hopkins University School of Medicine) for her help in preparing this Commentary. Work in the Casero laboratory is supported by grants from the NIH (CA204345), the Maryland Cigarette Restitution Fund, and the Samuel Waxman Cancer Research Foundation. Funding Information: The author thanks Tracy Murray Stew art (Johns Hopkins University School of Medicine) for her help in preparing this Commentary. Work in the Casero laboratory is supported by grants from the NIH (CA204345), the Maryland Cigarette Restitution Fund, and the Samuel Waxman Cancer Research Foundation. Publisher Copyright: {\textcopyright} 2018 American Society for Clinical Investigation. All rights reserved.",
year = "2018",
month = oct,
day = "1",
doi = "10.1172/JCI123266",
language = "English (US)",
volume = "128",
pages = "4254--4256",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "10",
}